H.C. Wainwright says Cidara Therapeutics (CDTX) announced several positive updates to the planned Phase 3 study of its lead asset, CD388, following a meeting with the FDA. The Phase 3 study is now accelerated by six months, in time for the fall 2025 Northern Hemisphere flu season, the analyst tells investors in a research note. In addition, the FDA guided that if successful, a single trial of CD388 will be sufficient for a approval submission, adds H.C. Wainwright. The reiterates Cidara as a top pick with a Buy rating and $74 price target The stock in morning trading is up 14% to $83.56.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDTX:
- Cidara Therapeutics price target raised to $137 from $115 at RBC Capital
- Cidara Therapeutics announces expanded, accelerated Phase 3 plan for CD388
- Cidara Therapeutics price target raised to $123 from $45 at WBB Securities
- Cidara Therapeutics presents data on CD388 from Phase 2b NAVIGATE trial
- Cidara Therapeutics: Promising Trials Amidst Financial Challenges